Mid Ohio Oncology/Hematology Inc., DBA The Mark H. Zangmeister Center

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia2 trials
• Bladder cancer1 trial
• Chronic lymphocytic leukaemia1 trial
• Chronic myeloid leukaemia1 trial
• Diffuse large B-cell lymphoma1 trial
• Follicular lymphoma1 trial
• Mantle cell lymphoma1 trial
• Multiple myeloma1 trial
• Myelodysplastic syndromes1 trial
• Myeloproliferative neoplasms1 trial

Phase

• Phase 41 trial

Status

• Active, not recruiting1 trial
• Terminated1 trial

Lead sponsor

• Celgene1 trial
• Pharmacyclics Switzerland GmbH1 trial

Running trials

• Active, not recruiting

  Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

  NCT03229200· Phase 4· Pharmacyclics Switzerland GmbH· Source

Closed trials

• Terminated

  Connect® Myeloid Disease Registry

  NCT01688011· Celgene· Source